Abstract
We present the case of a 77-year-old male patient with more than 50 basal cell carcinomas on the head and upper trunk. The patient did not respond to several lines of treatment, including surgery, imiquimod, retinoids, itraconazole and therapy with the hedgehog inhibitor vismodegib. The patient responded well to off-label therapy with the anti-programmed death-1 antibody pembrolizumab after four infusions.
© 2018 British Association of Dermatologists.
MeSH terms
-
Aged
-
Antibodies, Monoclonal, Humanized / administration & dosage*
-
Basal Cell Nevus Syndrome / drug therapy*
-
Basal Cell Nevus Syndrome / genetics
-
Basal Cell Nevus Syndrome / immunology
-
Humans
-
Infusions, Intravenous
-
Male
-
Mutation
-
Off-Label Use
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
-
Repressor Proteins / genetics*
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / genetics
-
Skin Neoplasms / immunology
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Humanized
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor
-
Repressor Proteins
-
SUFU protein, human
-
pembrolizumab